文献速递肝病

一般人群中12种体成分指标对代谢功能障碍相关脂肪性肝病、高危代谢功能障碍相关脂肪性肝炎及肝脏硬度增加的预测价值比较

A Comparison of the Predictive Value of 12 Body Composition Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease, At-Risk Metabolic Dysfunction-Associated Steatohepatitis, and Increased Liver Stiffness in a General Population Setting.
PubMed 文献 · Am J Gastroenterol · 2025-07-23

该研究基于2017-2023年美国国家健康与营养调查中11,579名有肝脏健康数据的成人,比较12种体成分指标对代谢功能障碍相关脂肪性肝病(MASLD)、高危代谢功能障碍相关脂肪性肝炎(MASH)及肝脏硬度测量值(LSM)增加的预测能力。结果显示腰围(WC)对MASLD(AUC 0.82)、高危MASH(AUC 0.73)和LSM增加(AUC 0.75)的预测价值最高,优于或等于所有其他指标。WC与MASLD风险呈非线性关联,超过100 cm后风险略有饱和;高危MASH呈线性关联;LSM增加风险仅在WC>100 cm后上升。

要点

  • 在一般人群中,腰围(WC)对MASLD、高危MASH和LSM增加的预测AUC分别为0.82、0.73和0.75,优于或等于其他11种体成分指标。
  • WC与MASLD风险呈非线性关联,超过100 cm后风险略有饱和;高危MASH呈线性关联;LSM增加风险仅在WC>100 cm后上升。
  • 即使WC<100 cm,MASLD和高危MASH风险仍增加;而LSM增加风险仅在WC>100 cm后上升。

核心结论

  • 在一般人群中,MASLD和高危MASH风险在WC<100 cm时即已增加,而LSM增加风险仅在WC>100 cm后上升。
  • 尽管差异相对较小,WC对MASLD、高危MASH和LSM增加的预测价值始终最高,因此最适合用于MASLD的诊断、管理和风险分层。

研究设计与样本

  • 研究纳入2017-2023年美国国家健康与营养调查(NHANES)中有肝脏健康数据的成年参与者。
  • 排除标准为年龄大于80岁、过量饮酒(>60 g/d)、病毒性肝炎和缺失人体测量数据。
  • MASLD定义为受控衰减参数≥275 dB/m且伴代谢功能障碍;MASH定义为FibroScan-天冬氨酸氨基转移酶≥0.35;LSM增加定义为≥8 kPa。
  • 采用曲线下面积(AUC)分析评估12种体成分参数的预测性能,并以限制性立方样条评估非线性。

主要发现

  • 共纳入11,579名参与者(年龄51[35-63]岁,47%为男性),其中41%患有MASLD,6.5%为高危MASH,9.9%为LSM增加。
  • 腰围(WC)而非BMI或腰高比对MASLD的AUC最高(0.82),对高危MASH的AUC为0.73,对LSM增加的AUC为0.75,在所有亚组中优于或等于所有其他指标。
  • WC与MASLD的关联呈非线性,超过100 cm后风险略有饱和;高危MASH在整个范围内呈线性关联;LSM增加风险仅在WC>100 cm后上升。

关键数值与推荐

  • MASLD定义为受控衰减参数≥275 dB/m且伴代谢功能障碍。
  • MASH定义为FibroScan-天冬氨酸氨基转移酶≥0.35。
  • LSM增加定义为≥8 kPa。
  • WC对MASLD的AUC为0.82,对高危MASH的AUC为0.73,对LSM增加的AUC为0.75。

临床怎么用

  • 作者认为WC对MASLD、高危MASH和LSM增加的预测价值最高,因此最适合用于MASLD的诊断、管理和风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Adipose tissue is a key mediator of metabolic dysfunction-associated steatotic liver disease (MASLD) development and progression into metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Since direct comparisons of body composition parameters are lacking, we here investigate 12 different body composition parameters. METHODS: Adult participants from National Health and Nutrition Examination Survey 2017-2023 with liver health data were included. Exclusion criteria were age older than 80 years, excessive alcohol (>60 g/d), viral hepatitis, and missing anthropometrics. MASLD was defined as controlled attenuation parameter ≥275 dB/m with metabolic dysfunction, MASH as FibroScan-aspartate aminotransferase ≥0.35, and increased liver stiffness measurement (LSM) as ≥8 kPa. Predictive performance of 12 body composition parameters was assessed using area under the curve analysis. Predicted probabilities of outcomes were visualized for standardized parameters, and nonlinearity was assessed through restricted cubic splines. RESULTS: Among 11,579 participants (age 51 [35-63], 47% male), 41% had MASLD, 6.5% at-risk MASH, and 9.9% increased LSM. Waist circumference (WC) and not BMI or waist-to-height ratio obtained the highest area under the curve for MASLD (0.82), at-risk MASH (0.73), and increased LSM (0.75) outperforming or equaling all other indices across subgroups. Associations between WC and MASLD were nonlinear, with slight risk saturation beyond 100 cm; at-risk MASH was linearly associated across the entire spectrum; and increased LSM risk rose only after WC >100 cm. DISCUSSION: In the general population, MASLD and MASH risk increased even when WC < 100 cm, while increased LSM risk was increasing only >100 cm. Although relatively minor differences, WC consistently demonstrated the highest predictive value for MASLD, at-risk MASH, and increased LSM and therefore most suited for MASLD diagnosis, management, and risk stratification.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. van Kleef LA, Michel M, Savas M, et al. A Comparison of the Predictive Value of 12 Body Composition Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease, At-Risk Metabolic Dysfunction-Associated Steatohepatitis, and Increased Liver Stiffness in a General Population Setting. Am J Gastroenterol. 2025. PMID: 40699281. doi:10.14309/ajg.0000000000003657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。